EarLy Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT): a Parallel Group, Randomized, Double Blind, Placebo Controlled Trial

Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting > 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.

开始日期2026-01-01

申办/合作机构

Sunnybrook Health Sciences Centre

NCT07035197

/ RecruitingN/AIIT

Facilitators and Barriers to Eptinezumab Administration in Thailand: Real-World Experiences and Perspectives From Mixed-method Design and In-Depth Interviews (FACEpi)

This research study is designed as a longitudinal prospective descriptive study using mixed-method data collection. Eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody (anti-CGRP mAb), is administered by intravenous (IV) infusion every 3 months as preventive medication for individuals with migraine who have been diagnosed based on theInternational Classification of Headache Disorders, 3rd edition (ICHD-3) by headache specialist neurologists. The goal of this study is to understand the real-life experiences of people with migraine who receive eptinezumab in a hospital setting in Thailand, a middle-income country. The researchers want to learn about what makes it easier or harder for patients and healthcare workers to use this treatment.
The main questions it aims to answer are:
* What are the barriers and facilitators to using eptinezumab from the perspectives of patients and healthcare providers?
* Does eptinezumab reduce monthly migraine days and improve quality of life over time?
Participants will:
* (For migraine patients) Take part in an in-depth interview (IDI) within 24 hours after receiving an eptinezumab infusion
* (For migraine patients) Complete questionnaires about migraine symptoms, disability, and quality of life at baseline, 3 months, and 6 months
* (For healthcare providers) Take part in a one-time interview about their experiences administering eptinezumab
The study will also look at how well eptinezumab works by measuring changes in monthly migraine days and other health scores over a 6-month period. The information from this study may help improve migraine care in Thailand and support better access to new treatments like eptinezumab.

开始日期2025-08-25

申办/合作机构

H. Lundbeck A/S

100 项与艾普奈珠单抗相关的临床结果

登录后查看更多信息

100 项与艾普奈珠单抗相关的转化医学

登录后查看更多信息

100 项与艾普奈珠单抗相关的专利（医药）

登录后查看更多信息

225

项与艾普奈珠单抗相关的文献（医药）

2026-01-02·Expert Review of Neurotherapeutics

Medication-overuse headache: can anti-CGRP monoclonal antibodies replace withdrawal?

Review

作者: Allamprese, Rossana ; Boccalini, Alberto ; Pellesi, Lanfranco ; Lo Castro, Flavia ; Guerzoni, Simona

INTRODUCTION:

Medication-overuse headache (MOH) is a secondary headache disorder arising from the excessive use of acute headache medications, most commonly triptans and nonsteroidal anti-inflammatory drugs (NSAIDs). Traditional management relies on education strategies and drug withdrawal followed by preventive therapy, but relapse rates remain high and detoxification is not always feasible.

AREAS COVERED:

This review summarizes current evidence on anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies in migraine patients with medication overuse or MOH. A structured literature search was conducted in PubMed and Scopus for studies published up to August 2025. Erenumab, fremanezumab, galcanezumab and eptinezumab consistently reduced headache frequency, acute medication intake and disability, even when initiated without prior withdrawal of overused drugs. Rates of remission from MOH to non-overuse status were high, and safety profiles were comparable to those observed in general migraine populations.

EXPERT OPINION:

Anti-CGRP antibodies offer a targeted strategy capable of interrupting the cycle of overuse and sensitization underlying MOH. Early initiation of anti-CGRP therapy during ongoing overuse appears effective and well tolerated, but long-term outcomes are likely improved when treatment is accompanied by patient education and, in selected cases, structured withdrawal.

2025-12-01·EUROPEAN JOURNAL OF NEUROLOGY

Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2–4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER Trial

Article

作者: Soni‐Brahmbhatt, Seema ; Awad, Susanne F. ; Boserup, Line Pickering ; Asher, Divya ; Lee, Xin Ying ; Starling, Amaal J. ; Tassorelli, Cristina ; Sperling, Bjørn ; Goadsby, Peter J.

ABSTRACT:

Background:

This post hoc analysis examined the reduction in monthly headache days ( MHDs ) by frequency category shifts and associated improvements following eptinezumab treatment.

Methods:

The DELIVER trial evaluated eptinezumab in adults with migraine for whom 2–4 previous preventive treatments failed. During a 24‐week, double‐blind, placebo‐controlled period followed by a 48‐week extension period, participants received IV eptinezumab 100 mg, 300 mg, or placebo every 12 weeks, with all receiving eptinezumab beginning Week 25 (dose‐blinded). Participants were categorized by MHD frequency: > 14, 8–14, 4 to < 8, 1 to < 4, 0. MHD category shifts were evaluated in the total population and several subgroups (including participants with > 14 baseline MHDs and early ≥ 50% responders). In participants reporting < 8 MHDs after all doses, the associated changes in headache intensity and disease status were evaluated.

Results:

Of randomized participants, 88% (782/890) completed the trial. The percentage of participants randomized initially to eptinezumab who reported < 4 MHDs was 23% (138/592) over Weeks 1–12 and 47% (236/498) over Weeks 61–72; 9% reported 0 MHDs after the final dose. Of participants randomized initially to eptinezumab who shifted from ≥ 8 MHDs at baseline to < 8 over Weeks 1–12, 71% (170/241) reported < 8 MHDs for the rest of the trial; of those who shifted from > 14 to < 8 MHDs, 66% (49/74) reported < 8 MHDs for the rest of the trial. Reduction to < 8 MHDs was associated with robust improvements in headache intensity and disease burden.

Conclusions:

Eptinezumab was associated with sustained reduction in MHD category, with some achieving headache/migraine freedom in patients with a history of preventive treatments that failed.

Trial Registration:

ClinicalTrials.gov (identifier: NCT04418765; https://www.clinicaltrials.gov/ct2/show/NCT04418765 ) and EudraCT (identifier: 2019‐004497‐25; https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2019‐004497‐25 )

2025-11-01·CLINICAL NEUROLOGY AND NEUROSURGERY

Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon

Article

作者: Alsaffarini, Kareem ; Adel, Fatema ; Suliman, Reem ; El Jadam, Caline ; Pagdato, Beverly ; Alsaadi, Taoufik ; Alkhateri, Athra

INTRODUCTION:

The introduction of calcitonin gene-related peptide (CGRP)-targeted therapies, including monoclonal antibodies (mAbs) and gepants, has revolutionized migraine management by reducing attack frequency, severity, and duration. However, concerns have emerged regarding the potential wearing off effect, where treatment efficacy diminishes before the next scheduled dose. This study evaluates the long-term efficacy and safety of bridging CGRP mAbs with gepants across 16 clinic visits over 24 months of follow-up, to manage the wearing-off phenomenon of mAbs.

METHODS:

This was a retrospective, real-world, exploratory study. The participants included in the study were adult (≥ 18 years) patients diagnosed with migraine. Screening for patients who had received CGRP mAbs for a minimum of 12 months was done. Clinical data was collected from electronic medical records. A total of 439 patients with documented follow-up visits while taking CGRP mAbs were identified. Data was collected from one site, the American Center for Psychiatry and Neurology, Abu Dhabi, UAE.

RESULTS:

Out of the 493 patients, 65 patients had a wear-off effect of CGRP mAbs and were on bridging treatment. Eptinezumab (55.38 %) was the most prescribed CGRP mAb, followed by erenumab (26.15 %) and galcanezumab (18.46 %). Rimegepant (95.38 %) was the primary gepant used for bridging therapy. Weekly headache days (WHD) decreased significantly over the 16 visits, from 4 days at baseline to near zero by visit 16. 41.54 % of patients improved in severity, while 46.15 % remained stable.

CONCLUSION:

These findings strongly suggest the effectiveness of gepants in managing the wearing-off phenomenon across patients on mAbs. They also underscore the importance of individualized treatment approaches. While CGRP-targeted treatments remain highly effective, ongoing research is essential to optimize long-term use and minimize fluctuations in efficacy, ultimately improving patient reported outcomes.

136

项与艾普奈珠单抗相关的新闻（医药）

2026-01-04

·钻研生物的王小喵

告别“电钻钻头”之痛！偏头痛迎来预防性治疗新希望

点击上方关注我们本文旨在进行前沿医学科普，传达新药研发信息，不能替代专业医疗建议。你是否曾经历过这样的剧痛——仿佛有一把无形的电钻在太阳穴上工作，伴随恶心、畏光、畏声，只想蜷缩在黑暗的房间里，任何日常计划都被彻底打乱？这不是简单的“头疼”，而是偏头痛。对于每月发作超过8天的慢性偏头痛患者而言，生活常被疼痛绑架。近日，一则消息为这些患者带来了新曙光：灵北公司的偏头痛预防新药艾普奈珠单抗已向国家药监局提交上市申请，有望为国内患者提供一种从根源上减少发作的创新选择。不仅仅是“头疼”：被低估的疾病负担偏头痛是一种复杂的神经系统疾病，其特征不仅仅是单侧、搏动性的中重度疼痛。发作时，患者常伴随恶心、呕吐，并对光线、声音甚至气味异常敏感。一次发作可持续数小时至数天，严重损害工作能力、学习效率和生活质量。更令人担忧的是治疗误区。许多患者将偏头痛视为“急性病”，仅在疼痛来袭时服用止痛药。然而，长期频繁使用急性止痛药（尤其是每月超过10-15天），可能导致 “药物过量性头痛” ，陷入“疼痛-服药-更易疼痛”的恶性循环，让治疗变得愈发棘手。这种绝望，唯有亲历者方能深切体会。治疗新范式：从“被动止痛”到“主动预防” 与传统止痛药“救火”式的思路不同，艾普奈珠单抗属于 “预防性治疗” 药物。它的目标不是等疼痛发生了再去压制，而是通过规律用药，从源头上减少偏头痛的发作频率和严重程度，帮助患者重获对生活的掌控感。其作用机制直指病因核心。研究发现，偏头痛发作时，患者体内一种名为 “降钙素基因相关肽（CGRP）” 的神经递质水平会显著升高。CGRP就像一道强大的“疼痛指令”，它能引起脑血管扩张和神经炎症，从而触发头痛。艾普奈珠单抗是一种靶向CGRP的单克隆抗体，它能精准地结合并中和CGRP，阻断这条疼痛信号的传递通路，相当于为过度兴奋的神经系统安装了一个“稳定器”。新药优势：更快起效，数据更贴合亚洲人群如果获批，艾普奈珠单抗将在国内偏头痛预防治疗领域提供具有竞争力的新选择，其优势主要体现在： 1.静脉给药，可能更快起效：与部分需要患者自行皮下注射的同类药物相比，该药通过静脉输注给药，药物能更快速、更充分地进入血液循环，有助于患者更快地获得病情稳定。 2.拥有扎实的亚洲人群数据：其关键的III期临床试验（SUNRISE研究）主要针对亚洲慢性偏头痛患者开展。研究结果显示，该药能显著减少患者的每月偏头痛发作天数，并对减轻中重度疼痛程度有积极作用，且安全性良好。这为未来在中国患者中的应用提供了更直接、更令人放心的证据。 3.为患者增加重要选择：目前国内获批的同类靶向预防药物选择有限。该药的上市，将丰富临床治疗选择，尤其为那些对传统预防药物（如某些降压药、抗抑郁药）不耐受或效果不佳的患者，提供了一个新的希望。谁可能从中受益？根据其临床试验的设计，以下特征的慢性偏头痛患者，未来可能成为该药的适用人群（最终以药品说明书及医生判断为准）：确诊为慢性偏头痛：即每月偏头痛发作天数≥8天，且头痛总天数在15天以上。病史较长：偏头痛病史通常超过1年。年龄：通常在18至75岁之间，且首次偏头痛发作在50岁之前。未使用过其他CGRP靶向药：此前未使用过同类作用机制的预防药物。值得注意的是，并非所有患者都适用。例如，合并有其他复杂疼痛综合征或特定疾病的患者需由神经科医生严格评估。用药必须遵医嘱，不可自行判断。艾普奈珠单抗的上市申请，标志着我国偏头痛治疗正与国际接轨，从“发作后止痛”向“发作前预防”的科学管理理念迈进。这不仅是药物的进步，更是对患者生活质量的深切关怀。我们期待该药能早日获批，并通过合理的定价和医保政策，让更多深受困扰的患者能够受益。请记住，偏头痛不是“矫情”，也不是必须硬扛的“宿命”。它是一种需要被正视、可以被科学管理的疾病。主动寻求神经科医生的专业帮助，了解前沿的治疗方案，正是从疼痛手中夺回生活主导权的第一步。 ●告别频繁输液！血友病迎来每周一针的“自由”新生活 ●国产“精准导弹”问世，击破鼻咽癌后线治疗困局

疫苗临床3期

2025-12-31

·百度百家

诺华Erenumab引领偏头痛治疗革命，CGRP药物市场竞争白热化

△ Erenumab药物概述 4月7日，CDE官网公布，诺华与安进携手研发的偏头痛新药 Erenumab注射液已正式提交上市申请，并获受理。这款药物旨在预防成人偏头痛，标志着国内首款抗CGRPR单抗的申报上市。 Erenumab是一种全人源IgG2单抗，通过拮抗CGRP受体功能为偏头痛患者提供新的治疗选择。自2018年5月获FDA批准上市以来，Erenumab已在全球范围内成为首个针对CGRP受体的抗体药物。随后，该药于2018年7月在欧盟获准上市。据药企财报显示，Erenumab在2021年的销售收入达到5.32亿美元，彰显其广阔的市场前景。迄今为止，该药物已在日本、欧盟、英国、加拿大、澳大利亚等七十多个国家获得批准，为全球患者带来福音。 △ DRAGON研究结果 2021年3月，诺华公布了DRAGON III期研究的积极结果，该研究以评估Erenumab在预防成人慢性偏头痛方面的有效性和安全性为主要目的。诺华的DRAGON III期研究显示，Erenumab在预防慢性偏头痛方面效果显著。这是一项随机双盲、多中心、安慰剂对照的III期临床试验，共纳入557例患者，其中中国人群占比较大。研究显示，在12周的双盲治疗期最后4周，Erenumab 70mg组在降低每月偏头痛天数（MMD）方面显著优于安慰剂组。同时，Erenumab 70mg组的每月偏头痛天数相比基线减少50%以上的应答率也显著高于安慰剂组。此外，Erenumab的安全性特征与安慰剂组相似，未发现新的安全性问题。 △ 全球偏头痛市场潜力偏头痛，作为一种常见的三叉神经血管性头痛，全球发病率排名第三，是导致残疾的重要原因。在美国，超过3300万人受到其影响，而在中国，约有1.3亿患者，其中女性患病率是男性的三倍。偏头痛不仅给患者带来巨大的痛苦，还带来了沉重的经济负担。在欧盟，每年因偏头痛导致的医疗费用和生产力损失高达1110亿欧元；在美国，这一数字更是达到约800亿美元。偏头痛药物市场潜力巨大，预计到2027年市场规模将突破110亿美元，其中CGRP药物将占据65亿美元以上的份额，特别是口服CGRP拮抗剂，有望突破40亿美元。在我国，偏头痛患者数量高达1.34亿，市场潜力巨大。诺华的Erenumab已在美市场取得佳绩，并率先在中国上市，抢占先机。 △ 治疗现状与挑战目前，偏头痛的治疗方式主要包括急性救治和预防性治疗，但现有的治疗药物仍无法满足临床需求。尽管曲谱坦类药物能缓解偏头痛发作时的症状，但其并不能预防偏头痛的再次发作，且服用后两小时内无疼痛缓解的患者仅占约30%。此外，曲谱坦类药物还存在心血管风险，这进一步限制了其临床应用。因此，急需新药打破困境。当前，预防偏头痛最常用的处方药包括抗癫痫药（例如托吡酯）、β受体阻滞剂（如普纳洛尔）和三环类抗抑郁药（如阿米替林）。然而，这些药物往往伴随着明显的副作用，如认知问题、疲劳、嗜睡和体重增加等。 △ CGRP药物的竞争与发展偏头痛药物的突破性进展在于靶向CGRP/CGRPR药物的出现。随着对偏头痛病理机制研究的深入，科学家发现三叉神经疼痛是大脑的主要疼痛通路。他们希望阻断这条通路以终止疼痛感受。在研究过程中，降钙素基因相关肽（CGRP）引起了科学家的注意，由于其临床有效性，CGRP药物研发成为热门。随着对偏头痛病理机制研究的深入，科学家发现三叉神经疼痛是大脑的主要疼痛通路。这项发现引发了药物研发的热潮，多个公司已获FDA批准，市场竞争激烈。2018年标志着偏头痛药物市场的新起点，因为三款CGRP单抗药物相继获得美国食品药品监督管理局（FDA）的批准。自此以后，全球范围内已有七款针对CGRP通路的偏头痛疗法获得上市批准，其中既涵盖了针对CGRPR和CGRP的单抗药物，也包括了CGRP拮抗剂类化学药物。偏头痛市场备受瞩目，2027年预计全球市场规模将突破110亿美元，其中CGRP药物将占据65亿美元以上的份额。诺华的Aimovig、礼来的Emgality以及艾尔建的Ubrelvy都取得了不俗的销售业绩，尤其是Emgality，销售额反超诺华。而灵北的Vyepti和Biohaven的Nurtec也在市场中占据一席之地。值得一提的是，Nurtec作为唯一获批的速效口崩片，其服用方便性备受推崇。价格高昂是其普及的障碍。首批上市的CGRP/CGRPR单抗药物价格相当，每支约为600美元，年治疗费用约为6000美元。尽管面临挑战，但CGRP药物凭借其优良的安全性和高生物利用度，在偏头痛治疗领域的核心地位似乎已不可动摇。展望未来，该领域的市场竞争格局仍值得期待。

财报临床3期上市批准

2025-12-15

·生物通

神经疾病治疗新进展：从偏头痛急性治疗到Dravet综合征的疾病修饰疗法

在神经疾病治疗领域，2025年见证了多项突破性进展。偏头痛作为全球第二大致残性疾病，其急性治疗和预防性管理仍面临巨大挑战。传统非甾体抗炎药(NSAIDs)因起效慢、生物利用度低等问题，难以满足急性发作时的快速镇痛需求。而慢性偏头痛患者常因镇痛药过度使用陷入药物过量性头痛(MOH)的恶性循环，现有治疗策略对这类复杂病例往往力不从心。与此同时，罕见神经系统疾病如Dravet综合征更是缺乏疾病修饰疗法，患者长期依赖效果有限的对症治疗。针对这些临床痛点，研究人员在药物剂型革新、新型生物制剂和基因靶向治疗等领域取得系列突破。其中最具代表性的Celecoxib口服液(Elyxyb?)通过微乳剂技术成功克服了COX-2抑制剂疏水性难题，使血药浓度达峰时间从传统胶囊的2.5小时缩短至42分钟。两项随机对照试验证实，用药2小时后34%患者实现疼痛完全缓解，57%患者摆脱最严重伴随症状。这一创新制剂已被纳入德国S1偏头痛治疗指南，为急性发作提供新选择。在难治性偏头痛治疗方面，RESOLUTION研究首次证实CGRP单抗(Eptinezumab)联合标准化教育干预(BEI)对MOH患者的协同效应。608例患者数据显示，联合治疗4周后月头痛天数较基线减少6.9天，显著优于单用BEI组(3.7天)。特别值得注意的是，简短教育干预本身已能有效降低药物滥用频率，而联合方案在生活质量量表(HIT-6)和患者整体印象变化(PGIC)评分中展现更大优势。对于Dravet综合征这类遗传性癫痫脑病，反义寡核苷酸药物Zorevunersen的研发标志着疾病修饰治疗的重要里程碑。68周随访数据显示，接受70mg负荷剂量后以45mg维持治疗的患者，在认知和行为维度获得持续改善。基于这些结果设计的III期EMPEROR试验有望为这一致死性疾病带来首款改变病程的疗法。在注意力缺陷多动障碍(ADHS)领域，数字化健康应用(DiGA)的整合正重塑治疗范式。首款针对ADHS患儿家长的认证应用hiToco?，将行为治疗原理转化为可交互的案例教学，为家庭提供实时指导。这种数字化干预与传统药物(如上市25年的Medikinet)的结合，凸显了神经精神疾病治疗向多维化发展的趋势。主要技术方法：研究采用随机对照试验设计评估Celecoxib口服液疗效(n>1000)；通过III期临床试验EMPOWER研究Zorevunersen在Dravet综合征患者(n=68)中的长期效果；利用多中心IV期研究RESOLUTION比较Eptinezumab+BEI与单用BEI对慢性偏头痛合并MOH患者(n=608)的差异；应用数字化健康应用(DiGA)平台开展父母指导培训的实效性研究。研究结果 1.Celecoxib口服液的药代动力学特征通过微乳剂技术显著提高肠道渗透性，最大血药浓度达峰时间仅42分钟，较传统制剂提速3倍以上。 2.Zorevunersen的长期疗效数据 68周随访显示接受70mg负荷剂量治疗的患者在认知和行为评分持续改善，严重运动性发作频率显著下降。 3.Eptinezumab联合BEI的协同效应联合治疗组在4周时月头痛天数减少值较对照组多3.2天(P<0.01)，头痛影响测试(HIT-6)和患者整体印象变化(PGIC)评分改善更显著。 4.数字化干预在ADHS管理中的应用 hiToco?作为首款ADHS相关认证DiGA，通过案例化教学使治疗师和家长获得实操性指导，填补非药物治疗资源缺口。结论与展望系列研究证实剂型创新能显著提升经典药物的临床价值。Celecoxib口服液通过药剂学突破重新定义偏头痛急性治疗标准；CGRP靶向治疗与行为干预的整合为复杂病例提供新范式；反义寡核苷酸疗法在遗传性癫痫疾病中展现疾病修饰潜力；数字化工具的引入正重构神经精神疾病的管理生态。这些进展共同推动神经疾病治疗从症状控制向全程管理转型，为个体化治疗提供更多选择。

寡核苷酸临床3期临床结果临床2期突破性疗法

100 项与艾普奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾普奈珠单抗	L01XC	DB14040

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Lundbeck Seattle BioPharmaceuticals, Inc.	2020-02-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
药物引起的头痛	临床3期	美国	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	韩国	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	美国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国台湾	H. Lundbeck A/S	2021-02-17
丛集性头痛	临床3期	美国	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	日本	H. Lundbeck A/S	2020-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05452239 (CTgov)	临床4期	偏头痛 \| 继发性头痛症	608	Eptinezumab (Placebo-controlled Period: Eptinezumab)	獵範觸憲餘範觸鏇簾蓋(鏇窪蓋構衊憲齋鏇繭鑰) = 製齋窪窪網醖簾簾齋範網醖選簾鹹糧顧鹹願鬱 (窪積積製構衊鹽製襯構, 0.518) 更多	-	2025-12-04
				placebo+eptinezumab (Placebo-controlled Period: Placebo)	獵範觸憲餘範觸鏇簾蓋(鏇窪蓋構衊憲齋鏇繭鑰) = 遞鏇憲鹽顧鹹鬱齋獵範網醖選簾鹹糧顧鹹願鬱 (窪積積製構衊鹽製襯構, 0.519) 更多
NCT04921384 (SUNRISE, Pubmed \| Cephalalgia)	临床3期	偏头痛	978	Eptinezumab 100 mg	-	积极	2025-10-01
				Eptinezumab 300 mg
NCT05064371 (SUNSET, PRNewswire) 人工标引	临床3期	偏头痛	159	Eptinezumab 100 mg	廠膚蓋艱範網鬱蓋積淵(憲窪糧積窪鏇鬱夢艱壓) = 膚淵觸遞積衊醖窪鏇夢選糧鬱製構鹹艱繭鹹齋 (淵鏇構鏇衊壓簾夢夢選 )	积极	2025-09-11
				Eptinezumab 300 mg	-
RESOLUTION (PRNewswire) 人工标引	临床4期	偏头痛 \| 头痛	608	brief educational intervention (BEI) + eptinezumab	積鏇網繭範餘積糧壓簾(齋鬱窪積憲選襯簾壓襯) = 醖膚鏇鑰顧鑰鑰觸襯廠蓋艱衊網繭獵獵蓋蓋憲 (窪衊壓淵遞簾鬱艱艱顧 ) 更多	积极	2025-09-11
				brief educational intervention (BEI) + placebo	-
NCT04688775 (ALLEVIATE, Pubmed \| JAMA Neurol) 人工标引	临床3期	丛集性头痛	231	Eptinezumab 400 mg	艱餘鑰構鏇醖膚範鹽鹽(繭網願繭夢膚鏇膚艱壓) = 遞膚醖選網齋構膚鹽積製壓範鹹憲艱鏇鹹觸構 (衊憲築構觸糧憲遞製壓, 8.1) 更多	积极	2025-07-01
				Placebo	艱餘鑰構鏇醖膚範鹽鹽(繭網願繭夢膚鏇膚艱壓) = 繭顧壓壓遞艱蓋願簾膚製壓範鹹憲艱鏇鹹觸構 (衊憲築構觸糧憲遞製壓, 8.3) 更多
P12-12.010 (AAN2025)	N/A	偏头痛	94	Eptinezumab (≥75% increase in good days/month)	窪壓衊艱蓋艱壓選壓衊(鑰鑰蓋餘糧繭觸製艱廠) = 淵糧鹹鹹鹽艱簾積憲鏇淵遞鏇範膚繭網鬱艱壓 (構憲鏇觸範願選糧餘衊 )	积极	2025-04-07
				Eptinezumab (<75% increase in good days/month)	窪壓衊艱蓋艱壓選壓衊(鑰鑰蓋餘糧繭觸製艱廠) = 蓋簾範窪觸夢顧襯鹽選淵遞鏇範膚繭網鬱艱壓 (構憲鏇觸範願選糧餘衊 )
AAN2025	临床3期	偏头痛	128	Eptinezumab 300 mg	鏇醖範鹽鹽襯憲鑰鬱構(簾範獵願廠蓋鹹蓋醖壓) = 願糧鹽製繭遞簾觸網鑰觸醖餘鹹鏇簾糧範淵窪 (獵襯範餘鹽糧簾餘築鹽 ) 更多	积极	2025-04-07
AAN2025	临床3期	偏头痛维持	858	Eptinezumab 100 mg	簾構觸衊鹹窪蓋齋蓋鹹(醖遞夢製範製淵膚衊網) = 鑰願積鏇獵觸艱壓夢齋願遞積淵願淵築觸選糧 (廠艱蓋獵製淵鹹膚壓繭 ) 更多	积极	2025-04-07
				Eptinezumab 300 mg	簾構觸衊鹹窪蓋齋蓋鹹(醖遞夢製範製淵膚衊網) = 願願願顧壓構顧廠廠憲願遞積淵願淵築觸選糧 (廠艱蓋獵製淵鹹膚壓繭 ) 更多
NCT02974153 (PROMISE-2, Pubmed \| J Neurol)	临床3期	偏头痛 \| 头痛	1,072	Eptinezumab	範願夢齋廠糧壓衊襯鹹(鹽憲憲窪觸鏇膚窪鏇醖) = 顧鹹選遞簾鹹襯鏇廠遞鹹膚願膚願願淵醖鑰鹽 (膚築繭構構鹹構窪廠範 ) 更多	-	2025-01-01
				Placebo	範願夢齋廠糧壓衊襯鹹(鹽憲憲窪觸鏇膚窪鏇醖) = 網鬱膚鑰繭鏇齋構窪觸鹹膚願膚願願淵醖鑰鹽 (膚築繭構構鹹構窪廠範 ) 更多
NCT04249427 (CTgov)	临床4期	过敏性鼻炎 \| 面部疼痛	29	Erenumab Prefilled Syringe (Erenumab)	簾遞願醖艱鏇鑰艱醖顧(築網積襯願蓋糧鹹繭襯) = 鑰顧夢夢鹽廠範夢鑰衊鬱鏇製衊鑰積齋鹹餘築 (繭製遞網糧膚積膚鹽選, 6.9) 更多	-	2024-09-24
				Placebo (Placebo)	簾遞願醖艱鏇鑰艱醖顧(築網積襯願蓋糧鹹繭襯) = 遞醖壓蓋襯膚窪窪蓋夢鬱鏇製衊鑰積齋鹹餘築 (繭製遞網糧膚積膚鹽選, 8.0) 更多